ROLE OF FRUCTOSE TRANSPORTER (GLUT5) EXPRESSION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Serene Xavier, 4160440

LONG NON-CODING RNAS AND THEIR ROLE ON EPIGENOME AS DIAGNOSTIC MARKERS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA OF T CELLS

EHA Library, Giovanni Smaldone, 4160441

EFFICACY AND SAFETY OF REGIMEN WITH OLVEREMBATINIB AND BLINATUMOMAB FOR THE FRONTLINE TREATMENT OF PH-POSITIVE OR PH-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Xiuli Xu, 4160443

REAL-WORLD OUTCOMES OF ADULT B-ALL PATIENTS WHO EXPERIENCE RELAPSED OR REFRACTORY DISEASE FOLLOWING BREXUCABTAGENE AUTOLEUCEL, A STUDY BY THE ROCCA CONSORTIUM

EHA Library, Rawan Faramand, 4160444

LONG-TERM OUTCOMES OF PEBL-ENGINEERED CD7 NANOBODY CAR-T (PA3-17 INJECTION) IN RELAPSED/REFRACTORY T-ALL/LBL: PHASE I TRIAL UPDATE

EHA Library, Meng Lv, 4160445

COMBINATION OF OLVEREMBATINIB AND VP REGIMEN AS FIRST-LINE THERAPY FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-ARM, MULTICENTRE, PHASE 2 TRIAL

EHA Library, Gaixiang Xu, 4160448

CLINICAL EFFICACY ANALYSIS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH EXTRAMEDULLARY DISEASE

EHA Library, Zhao defeng, 4160454

RELAPSE RISK AND OUTCOME OF DISCONTINUING ASPARAGINASE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, xingchen wang, 4160457

REAL WORLD DATA OF THE SAFETY AND EFFICACY OF TALICABTAGENE AUTOLEUCEL (HUMANIZED CD19 CAR-T) IN RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA FROM INDIA.

EHA Library, Hasmukh Jain, 4160458

TARGETING MAT2A ALTERS THE METHYLATION LANDSCAPE AND DNA DAMAGE RESPONSE IN MULTIPLE MYELOMA, REVEALING NOVEL COMBINATION STRATEGIES.

EHA Library, Lien Van Hemelrijck, 4160776

PERCENTAGE OF ACTIVATED CD4+ T LYMPHOCYTES AMONG T LYMPHOCYTES PREDICT HEMATOLOGIC RESPONSE TO IMMUNOSUPPRESSIVE THERAPY IN APLASTIC ANEMIA

EHA Library, Youzhen Xiong, 4160780

IN SILICO-IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY INDUCE CELL DEATH BY APOPTOSIS IN MULTIPLE MYELOMA CELLS AND LEAD TO THE ACTIVATION OF THE CGAS/STING PATHWAY.

EHA Library, Valentina Traini, 4160781

EXPLORING THE ROLE OF NONO IN TRANSCRIPTIONAL REGULATION OF CELLULAR PATHWAYS IN MULTIPLE MYELOMA: INSIGHTS INTO ITS PARASPECKLE-DEPENDENT AND INDEPENDENT REGULATORY MECHANISMS

EHA Library, Elisa Taiana, 4160782

MYELOMA-ASSOCIATED MACROPHAGES INDUCE DRUG-RESISTANCE THROUGH SREBP1-DEPENDENT LIPID METABOLIC DYSREGULATION IN MULTIPLE MYELOMA

EHA Library, Xing Guo, 4160784

RISK RECLASSIFICATION IN MULTIPLE MYELOMA: ASSESSING THE SHIFT FROM MSMART V3.0 TO V4.0

EHA Library, Jorge Arturo Hurtado Martinez, 4160785

UPDATED RESULTS OF A PHASE I OPEN-LABEL SINGLE-ARM STUDY OF DUAL TARGETING BCMA AND CD19 FASTCAR-T (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA

EHA Library, Juan Du, 4160786

LINVOSELTAMAB + BORTEZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL RESULTS FROM THE LINKER-MM2 TRIAL

EHA Library, Paula Rodríguez-Otero, 4160791

NARLUMOSBART COMPARED WITH DENOSUMAB IN THE TREATMENT OF BONE DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: A MULTICENTER, RANDOMIZED, CONTROLLED, NON-INFERIORITY STUDY

EHA Library, Fei Li, 4160792

DELETION 17P, AND IGH HIGH RISK TRANSLOCATIONS ALONG WITH CHROMOSOME 1 ABNORMALITIES ARE THE STRONGEST SURVIVAL PREDICTORS IN MULTIPLE MYELOMA: A REAL-WORLD VALIDATION BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Eirini Katodritou, 4160795

SIMULTANEOUS WHOLE-BODY MULTI-PARAMETRIC 2-[18F]FDG-PET/MRI IN SMOLDERING MULTIPLE MYELOMA ASSESSMENT : DIAGNOSTIC AND PROGNOSTIC IMPACT

EHA Library, Bastien Jamet, 4160804

AUTOLOGOUS B CELL MATURATION ANTIGEN (BCMA) AND CD19 DUAL TARGETING FASTCAR-T CELLS (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Juan Du, 4160806

BCMA-TARGETING BISPECIFIC T-CELL ENGAGERS WITH PROPHYLACTIC TOCILIZUMAB USE ARE SAFE AND INDUCE DEEP AND RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY STAGE 3 AL AMYLOIDOSIS

EHA Library, Romain Gounot, 4160807

DREAMM-7 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB + DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY IN PATIENTS BY SUBSEQUENT THERAPY

EHA Library, Vania Hungria, 4160809

TALQUETAMAB VS REAL-WORLD PHYSICIAN'S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN THERAPY: UPDATED ANALYSES OF MONUMENTAL-1 VS LOCOMMOTION/MOMMENT

EHA Library, María-Victoria Mateos, 4160811

RETROSPECTIVE REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN EUROPEAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT RECEIVING STEM CELL TRANSPLANTATION

EHA Library, Mamta Garg, 4160813

REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN (BELAMAF) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED IN EUROPE

EHA Library, Michele Cavo, 4160816

POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN NDMM PATIENTS WITH RENAL INJURY(RI): A MULTICENTER, RANDOMIZED CONTROLLED, OPEN-LABEL TRIAL

EHA Library, Jin Lu, 4160818

REAL-WORLD REASSESSMENT OF PROPOSED CLINICAL TRIAL CRITERIA AND TRANSLATIONAL FEATURES IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA

EHA Library, Sven Krippner, 4160822

INCREASED RISK OF INFECTIONS IN INDIVIDUALS WITH SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE SCREENED ISTOPMM STUDY

EHA Library, Lærke Sloth Andersen, 4160823

CARFILZOMIB AND LENALIDOMIDE FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: LONG-TERM FOLLOW-UP OF THE EMN12/HOVON-129 STUDY

EHA Library, Niels W C J van de Donk, 4160824

CARFILZOMIB-POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MYELOMA IN THE ERA OF QUADRUPLET THERAPY : A MULTICENTER REAL-WORLD STUDY

EHA Library, Pierre-Edouard Debureaux, 4160825

CLINICAL MANAGEMENT OF BELANTAMAB MAFODOTIN-ASSOCIATED OCULAR EVENTS: PRACTICAL GUIDANCE FROM THE BELAMAF EXPERT EXPERIENCE PROGRAM

EHA Library, Evangelos Terpos, 4160827

DEVELOPMENT OF A RISK STRATIFICATION ALGORITHM IN TRIPLE-CLASS EXPOSED (TCE) AND DOUBLE-CLASS EXPOSED (DCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) USING THE FLATIRON HEALTH DATABASE

EHA Library, Michel Delforge, 4160832

PROPHYLACTIC TOCILIZUMAB TO MITIGATE CYTOKINE RELEASE SYNDROME AND OUTPATIENT DOSING OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1/2 MONUMENTAL-1 RESULTS

EHA Library, Dominik Dytfeld, 4160835

CHARACTERIZATION OF INFECTIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF)-BASED REGIMENS FROM DREAMM-7 AND DREAMM-8 TRIALS

EHA Library, Pawel Robak, 4160837

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRANSPLANT-INELIGIBLE OR TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) IN THE PHASE 3 CEPHEUS TRIAL

EHA Library, Vania Hungria, 4160838

ADVANCED RISK PREDICTION FOR SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS THROUGH THE COMBINATION OF MAYO CLINIC'S 2/20/20 MODEL WITH TELOVIEW SMM RISK ASSESSMENT.

EHA Library, Shaji Kumar, 4160842

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH TWO TO FOUR LINES OF TREATMENT IN THE PREAMBLE REGISTRY

EHA Library, Claudio Cerchione, 4160843

EVALUATION OF A NOVEL PATIENT-REPORTED TOOL GUIDING EXTENDED DOSING SCHEDULE OF BELANTAMAB MAFODOTIN IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; UPDATED OPHTHALMIC SAFETY FROM A PHASE 1/2 TRIAL OF THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 4160844

IMPACT OF 1Q GAIN AND AMPLIFICATION IN PATIENTS TREATED WITH ANTI-CD38 MONOCLONAL ANTIBODIES. REAL WORLD DATA FROM A SINGLE CENTER IN SPAIN.

EHA Library, María Sánchez Tabernero, 4160848

AUTOLOGOUS STEM CELL TRANSPLANT - DOES IT BENEFIT MULTIPLE MYELOMA PATIENTS IN ERA OF CD38 MONOCLONAL ANTIBODIES?

EHA Library, Lay Khandwala, 4160850

MINIMAL CLONAL PLASMA CELL CONTAMINATION OF PERIPHERAL STEM CELL GRAFTS HAVE AN ADVERSE PROGNOSTIC IMPACT IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANTATION

EHA Library, Jin Lu, 4160851

HEPATIC RESPONSE DYNAMICS IN NEWLY DIAGNOSED LIGHT-CHAIN AMYLOIDOSIS PATIENTS

EHA Library, Chengyang Xu, 4160854

IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB (V) TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF US MM-6 BY RACE/ETHNICITY, RENAL FUNCTION, AND AREA INCOME

EHA Library, Ruemu Birhiray, 4160857

IDENTIFYING SYNERGISTIC ACTIVITIES OF COMBINED INHIBITION OF TYROSINE KINASES AND ANTI-APOPTOTIC MOLECULES IN ABL1 FUSION-POSITIVE ALL

EHA Library, Johanna Bender, 4160439

B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA CAUSES PARACRINE SENESCENCE IN MESENCHYMAL STROMAL CELLS TO SUBVERT THE TREATMENT RESPONSE IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA

EHA Library, Aditi Dey, 4160442

LEUKEMIC STEM CELL SIGNATURES IMPROVE RISK STRATIFICATION IN T-ALL PATIENTS

EHA Library, YI WEI Lee, 4160446

INOTUZUMAB OZOGAMICIN IN PEDIATRIC CD22-POSITIVE VERY HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF THE ITCC-059 STUDY

EHA Library, Erica Brivio, 4160447

MUTATIONS IN GENES ASSOCIATED WITH CLONAL HEMATOPOIESIS IN PATIENTS WITH ACUTE T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

EHA Library, Anastasia Vasileva, 4160449

HIGH IL7R DEFINES FAVORABLE T-ALL PROGNOSIS: CROSS-VALIDATION IN PEDIATRIC COHORTS

EHA Library, Senlin Zhang, 4160450

A RETROSPECTIVE STUDY OF RECIPIENT-DERIVED VERSUS DONOR-DERIVED CAR-T CELL THERAPY IN RELAPSED B-ALL PATIENTS AFTER TRANSPLANTATION

EHA Library, Lichao Liu, 4160451

PEGASPARGASE ADMINISTRATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AGED 55 YEARS OR OLDER TREATED WITH THE PEDIATRIC-INSPIRED PROGRAM LAL1913. A SUBANALYSIS OF THE CAMPUS ALL STUDY

EHA Library, Davide Lazzarotto, 4160452

MULTICENTER REAL-WORLD STUDY ON INOTUZUMAB AS A BRIDGE TO CELLULAR THERAPY IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Alicia Aguirre, 4160453

COMPARATIVE EFFICACY OF THE GIMEMA LAL1913 STANDARD CHEMOTHERAPY PROTOCOL VERSUS THE STANDARD ARM OF THE E1910 TRIAL IN MRD-NEGATIVE PH-NEGATIVE ALL: A MAIC ANALYSIS

EHA Library, Alfonso Piciocchi, 4160455

PROGNOSTIC SCORE MODELING FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Eduardo Chapchap, 4160456

THE STORY OF THE GUT MICROBIOME AND MULTIPLE MYELOMA: THE CHICKEN OR THE EGG?

EHA Library, Sylvia Faict, 4160777

PYGO2 IS OVEREXPRESSED BY CD138+ CELLS IN MULTIPLE MYELOMA PATIENTS WITH 1Q AMPLIFICATION IRRESPECTIVE OF CYTOGENETIC HETEROGENEITY: A NEW POSSIBLE DRUGGABLE TARGET

EHA Library, Nicolas Thomas Iannozzi, 4160778

PAEONIFLORIN ATTENUATES MOUSE MYELOMA BONE DISEASE BY REDUCING ERK 1 LEVELS IN THE EXOSOMES OF MULTIPLE MYELOMA CELLS

EHA Library, Xing Cui, 4160779

PREDICTIVE MODEL FOR NON-INVASIVE DIAGNOSIS AND PROGNOSIS OF MULTIPLE MYELOMA BY INTEGRATING LIQUID BIOPSY BIOMARKERS

EHA Library, Ana C. Queirós, 4160783

DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL

EHA Library, Philippe Moreau, 4160787

ELEVATED PROPORTIONS OF RESIDUAL BONE MARROW CLONAL PLASMA CELLS IN S-PHASE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IS ASSOCIATED WITH HIGH RISK OF EARLIER RELAPSE IN MULTIPLE MYELOMA PATIENTS

EHA Library, Tamer Hellou, 4160788

ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: A PHASE 2 STUDY BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 4160789

IMPACT OF MASS SPECTROMETRY ON THE EVALUATION OF MAINTENANCE TREATMENT IN PATIENTS WITH MYELOMA ENROLLED IN THE GEM2014MAIN TRIAL: INSIGHTS INTO TREATMENT RESPONSE AND DISEASE PROGRESSION

EHA Library, Noemi Puig, 4160794

BCMA-TARGETING T-CELL REDIRECTING BISPECIFIC ANTIBODY THERAPY POST-GPRC5D-DIRECTED BISPECIFIC ANTIBODY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (IFM 2024-13 BCMA POST-GPRC5D)

EHA Library, Cyrille Hulin, 4160796

POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ ANALYSIS

EHA Library, Elena Zamagni, 4160797

CILTACABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: CARTITUDE-4 SURVIVAL SUBGROUP ANALYSES

EHA Library, Yael Cohen, 4160798

EFFICACY AND SAFETY OF FRONTLINE ALTERNATING BORTEZOMIB-BASED REGIMENS PLUS DARATUMUMAB IN PRIMARY PLASMA CELL LEUKEMIA: INTERIM RESULTS OF EUMELEIA PHASE 2 TRIAL BY THE GREEK MYELOMA STUDY GROUP.

EHA Library, Eirini Katodritou, 4160799

EFFICACY OF RADIOTHERAPY AND ROLE OF ADJUNCTIVE IMMUNOCHEMOTHERAPY IN POEMS SYNDROME WITH SOLITARY PLASMACYTOMA

EHA Library, Wai Nga Grace Lau, 4160800

EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS (SC) PLUS CARFILZOMIB AND DEXAMETHASONE (ISA-KD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE PHASE 2 STUDY IZALCO

EHA Library, Gurdeep Parmar, 4160801

MEZIGDOMIDE (MEZI) IN NOVEL COMBINATIONS FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM THE CA057-003 TRIAL

EHA Library, Fredrik Schjesvold, 4160802

ABSOLUTE LYMPHOCYTE COUNT AS A KEY BIOMARKER FOR MONITORING SAFETY AFTER CILTACABTAGENE AUTOLEUCEL

EHA Library, Yi Lin, 4160803

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY

EHA Library, Thierry Facon, 4160805

ENHANCED REAL-WORLD OUTCOMES IN MULTIPLE MYELOMA FOLLOWING IMPLEMENTATION OF ALCYONE, CASSIOPEIA, MAIA, AND PERSEUS PROTOCOLS IN SWEDISH NATIONAL GUIDELINES: DATA FROM THE SWEDISH MYELOMA REGISTRY (2008-2024)

EHA Library, Cecilie Hveding Blimark, 4160808

IMPACT OF PLASMA CELL QUANTIFICATION METHODS ON IMWG DIAGNOSTIC CRITERIA: A COMPARATIVE STUDY USING WHOLE-SLIDE IMAGING BY QUPATH ON BONE MARROW SMEARS, CD138-IMMUNOSTAINED CLOTS, AND BIOPSIES IN MGUS AND SMM DIAGNOSIS

EHA Library, Atsushi Uehara, 4160810

UPDATED COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN'S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hermann Einsele, 4160812

SECOND PRIMARY MALIGNANCY IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA IN SWEDEN 2008-2017: RESULTS FROM A POPULATION-BASED STUDY

EHA Library, Ingigerdur Sverrisdottir, 4160814

OM336, A B CELL MATURATION ANTIGEN (BCMA) TARGETING T CELL ENGAGER ANTIBODY, DEMONSTRATES INITIAL SAFETY AND EFFICACY IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM)

EHA Library, Charlie Zhou, 4160815

CYSTATIN C AS BIOMARKER FOR THE EVALUATION OF THE EVALUATION OF RENAL OUTCOME IN RENAL AL AMYLOIDOSIS

EHA Library, Foteini Theodorakakou, 4160817

THE PHASE I/II TG01-STUDY - VACCINATING AGAINST RAS-MUTATED MULTIPLE MYELOMA

EHA Library, Hanne Marie Liddle Norseth, 4160819

CLINICAL UNMET NEED OF LENALIDOMIDE-REFRACTORY VS NON-LENALIDOMIDE-REFRACTORY PATIENTS WITH MULTIPLE MYELOMA IN THE HONEUR FEDERATED DATA NETWORK

EHA Library, Roman Hájek, 4160820

MULTICENTER PHASE 2 STUDY OF SUBCUTANEOUS ISATUXIMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA SC-VRD) IN NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA (NDMM TI): RESULTS FROM ISASOCUT (IFM 2022-05)

EHA Library, Arthur Bobin, 4160821

DIFFERENCES ACROSS COUNTRIES IN HEALTHCARE PROVIDER CONFIDENCE WITH CAR-T AND BISPECIFIC ANTIBODY THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Elena Zamagni, 4160826

COMPARATIVE ANALYSIS OF TREATMENT PATTERNS AND OUTCOMES IN 2,202 OCTOGENARIANS VS. 5,823 ELDERLY PATIENTS (70-

EHA Library, Irit Avivi Mazza, 4160828

THE IMPACT OF CHROMOSOME 1Q21 ABNORMALITIES ON FRONTLINE TREATMENT OUTCOMES IN CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: INSIGHTS FROM A MULTICENTER RETROSPECTIVE COHORT STUDY

EHA Library, Jian Cui, 4160829

CHARACTERIZING REAL-WORLD TREATMENT UTILIZATION AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AFTER LENALIDOMIDE AND ANTI-CD38 EXPOSURE IN THE UNITED STATES

EHA Library, Andrew J. Cowan, 4160830

A SINGLE-ARM, MULTI-CENTER, OBSERVATIONAL CLINICAL STUDY OF SELINEXOR COMBINED BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE REGIMEN FOR NEWLY DIAGNOSED MULTIPLE MYELOMA(NDMM) WITH HIGH-RISK FACTORS

EHA Library, Yuping Zhong, 4160831

DIFFERENCES IN INCIDENCE OF CYTOKINE RELEASE SYNDROME (CRS) AND IMPACT ON OVERALL SURVIVAL (OS) IN MULTIPLE MYELOMA PATIENTS TREATED WITH ANTI-BCMA VS. ANTI-GCPR5D BISPECIFIC ANTIBODIES: A REAL-WORLD ANALYSIS

EHA Library, Heidi Cho, 4160833

SOLUBLE SERUM FASL (SFASL) LEVELS IN MULTIPLE MYELOMA (MM) PATIENTS.

EHA Library, George Oikonomou, 4160834

CHARACTERIZATION OF OPHTHALMIC EXAMINATION FINDINGS (OEFS) AND IMPACT ON READING AND DRIVING IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF)

EHA Library, Roman Hájek, 4160836

OUTPATIENT STEP-UP DOSING AND SAFETY WITH TALQUETAMAB: A REAL-WORLD MAYO CLINIC STUDY

EHA Library, Shaji Kumar, 4160839

PROGNOSTIC IMPACT OF DYNAMIC CHANGES OF TYPE I MELANOMA ANTIGEN GENE PROTEINS CT7 (MAGE-C1/CT7) TRANSCRIPTS IN MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS

EHA Library, Jin Lu, 4160840

REAL-WORLD ANALYSIS OF TALQUETAMAB IN HEAVILY PRETREATED AND HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Carlyn Rose Tan, 4160841

REAL-WORLD OCULAR MONITORING AND SAFETY OF BELANTAMAB MAFODOTIN (BELAMAF) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED IN EUROPE AND THE US

EHA Library, Fredrik Schjesvold, 4160846

UNDERSTANDING THE BIOLOGY OF FRAILTY IN MYELOMA: JOINING SERUM PROTEOMICS WITH CLINICAL DATA USING MACHINE LEARNING

EHA Library, Adam Jones, 4160847

CORRELATION ANALYSIS BETWEEN INTENSIVE FOLLOW-UP MANAGEMENT STRATEGIES AND PROGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Junling Zhuang, 4160849

LONG-TERM FOLLOW-UP OF TANDEM AUTOLOGOUS VERSUS AUTOLOGOUS/ REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION FROM RELATED OR UNRELATED DONORS IN FIRST-LINE THERAPY IN 149 PATIENTS WITH HIGH-RISK MYELOMA

EHA Library, Song-Yau Wang, 4160852

A REAL-WORLD STUDY OF LENALIDOMIDE REFRACTORY MULTIPLE MYELOMA PATIENTS IN FINLAND: TREATMENT AND OUTCOMES

EHA Library, Marika Waltari, 4160853

EARLY RELAPSE AND HIGH-RISK FUNCTIONAL PROFILE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED FRONTLINE WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD)

EHA Library, Itziar Carro Arostegui, 4160855

INCIDENCE OF INFECTIONS AND MICROBIOLOGICAL PATTERN IN PATIENTS WITH MULTIPLE MYELOMA IN A REAL-WORLD POPULATION IN NORWAY

EHA Library, Juni Songe Paulsen, 4160856

OUTCOMES IN PATIENTS (PTS) WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH REAL-LIFE STANDARD OF CARE (SOC) THERAPIES IN LOCOMMOTION AND MOMMENT FINAL DATA

EHA Library, Katja Weisel, 4160858